RESUMEN
In this review for the Vivax malaria collection, Kamala Thriemer and colleagues explore efforts to eliminate P. vivax malaria.
Asunto(s)
Erradicación de la Enfermedad/estadística & datos numéricos , Malaria Vivax/prevención & control , Erradicación de la Enfermedad/normas , HumanosRESUMEN
Land use and land cover changes, such as deforestation, agricultural expansion and urbanization, are one of the largest anthropogenic environmental changes globally. Recent initiatives to evaluate the feasibility of malaria eradication have highlighted impacts of landscape changes on malaria transmission and the potential of these changes to undermine malaria control and elimination efforts. Multisectoral approaches are needed to detect and minimize negative impacts of land use and land cover changes on malaria transmission while supporting development aiding malaria control, elimination and ultimately eradication. Pathways through which land use and land cover changes disrupt social and ecological systems to increase or decrease malaria risks are outlined, identifying priorities and opportunities for a global malaria eradication campaign. The impacts of land use and land cover changes on malaria transmission are complex and highly context-specific, with effects changing over time and space. Landscape changes are only one element of a complex development process with wider economic and social dimensions affecting human health and wellbeing. While deforestation and other landscape changes threaten to undermine malaria control efforts and have driven the emergence of zoonotic malaria, most of the malaria elimination successes have been underpinned by agricultural development and land management. Malaria eradication is not feasible without addressing these changing risks while, conversely, consideration of malaria impacts in land management decisions has the potential to significantly accelerate progress towards eradication. Multisectoral cooperation and approaches to linking malaria control and environmental science, such as conducting locally relevant ecological monitoring, integrating landscape data into malaria surveillance systems and designing environmental management strategies to reduce malaria burdens, are essential to achieve malaria eradication.
Asunto(s)
Erradicación de la Enfermedad/estadística & datos numéricos , Salud Global , Malaria/prevención & control , Erradicación de la Enfermedad/normas , Ecosistema , HumanosRESUMEN
As neglected tropical diseases approach elimination status, there is a need to develop efficient sampling strategies for confirmation (or not) that elimination criteria have been met. This is an inherently difficult task because the relative precision of a prevalence estimate deteriorates as prevalence decreases, and classic survey sampling strategies based on random sampling therefore require increasingly large sample sizes. More efficient strategies for survey design and analysis can be obtained by exploiting any spatial correlation in prevalence within a model-based geostatistics framework. This framework can be used for constructing predictive probability maps that can inform in-country decision makers of the likelihood that their elimination target has been met, and where to invest in additional sampling. We evaluated our methodology using a case study of lymphatic filariasis in Ghana, demonstrating that a geostatistical approach outperforms approaches currently used to determine an evaluation unit's elimination status.
Asunto(s)
Erradicación de la Enfermedad/normas , Enfermedades Desatendidas/epidemiología , Enfermedades Desatendidas/prevención & control , Medicina Tropical , Simulación por Computador , Recolección de Datos , Humanos , Modelos Biológicos , PrevalenciaRESUMEN
BACKGROUND: The introduction of highly effective direct-acting antiviral (DAA) therapy for hepatitis C has led to calls to eliminate it as a public health threat through treatment-as-prevention. Recent studies suggest it is possible to develop a vaccine to prevent hepatitis C. Using a mathematical model, we examined the potential impact of a hepatitis C vaccine on the feasibility and cost of achieving the global WHO elimination target of an 80% reduction in incidence by 2030 in the era of DAA treatment. METHODS: The model was calibrated to 167 countries and included two population groups (people who inject drugs (PWID) and the general community), features of the care cascade, and the coverage of health systems to deliver services. Projections were made for 2018-2030. RESULTS: The optimal incidence reduction strategy was to implement test and treat programmes among PWID, and in settings with high levels of community transmission undertake screening and treatment of the general population. With a vaccine available, the optimal strategy was to include vaccination within test and treat programmes, in addition to vaccinating adolescents in settings with high levels of community transmission. Of the 167 countries modelled, between 0 and 48 could achieve an 80% reduction in incidence without a vaccine. This increased to 15-113 countries if a 75% efficacious vaccine with a 10-year duration of protection were available. If a vaccination course cost US$200, vaccine use reduced the cost of elimination for 66 countries (40%) by an aggregate of US$7.4 (US$6.6-8.2) billion. For a US$50 per course vaccine, this increased to a US$9.8 (US$8.7-10.8) billion cost reduction across 78 countries (47%). CONCLUSIONS: These findings strongly support the case for hepatitis C vaccine development as an urgent public health need, to ensure hepatitis C elimination is achievable and at substantially reduced costs for a majority of countries.
Asunto(s)
Erradicación de la Enfermedad , Hepacivirus/inmunología , Hepatitis C/prevención & control , Modelos Teóricos , Vacunación , Vacunas contra Hepatitis Viral/uso terapéutico , Antivirales/economía , Antivirales/uso terapéutico , Erradicación de la Enfermedad/economía , Erradicación de la Enfermedad/organización & administración , Erradicación de la Enfermedad/normas , Erradicación de la Enfermedad/estadística & datos numéricos , Hepatitis C/economía , Hepatitis C/epidemiología , Hepatitis C Crónica/economía , Hepatitis C Crónica/epidemiología , Hepatitis C Crónica/prevención & control , Humanos , Incidencia , Salud Pública/economía , Salud Pública/métodos , Abuso de Sustancias por Vía Intravenosa/economía , Abuso de Sustancias por Vía Intravenosa/epidemiología , Abuso de Sustancias por Vía Intravenosa/virología , Atención de Salud Universal , Vacunación/normas , Cobertura de Vacunación/economía , Cobertura de Vacunación/organización & administración , Vacunas contra Hepatitis Viral/economíaRESUMEN
OBJECTIVE: Australia's HPV vaccination and HPV-based cervical screening programs are changing the landscape in cervical cancer prevention. We aim to identify areas which can make the biggest further impact on cervical cancer burden. This protocol describes the first stage of a program of work called Pathways-Cervix that aims to generate evidence from modelled evaluations of interventions across the cervical cancer spectrum. METHODS: Based on evidence from literature reviews and guidance from a multi-disciplinary Scientific Advisory Committee (SAC), the most relevant evaluations for prevention, diagnosis and treatment were identified. RESULTS: Priority evaluations agreed by the SAC included: increasing/decreasing and retaining vaccination uptake at the current level; vaccinating older women; increasing screening participation; methods for triaging HPV-positive women; improving the diagnosis of cervical intraepithelial neoplasia (CIN) and cancer; treating cervical abnormalities and cancer; and vaccinating women treated for CIN2/3 to prevent recurrence. Evaluations will be performed using a simulation model, Policy1-Cervix previously used to perform policy evaluations in Australia. Exploratory modelling of interventions using idealised scenarios will initially be conducted in single birth cohorts. If these have a significant impact on findings then evaluations with more realistic assumptions will be conducted. Promising strategies will be investigated further by multi-cohort simulations predicting health outcomes, resource use and cost outcomes. CONCLUSIONS: Pathways-Cervix will assess the relative benefits of strategies and treatment options in a systematic and health economic framework, producing a list of 'best buys' for future decision-making in cervical cancer control.
Asunto(s)
Erradicación de la Enfermedad/métodos , Modelos Teóricos , Neoplasias del Cuello Uterino/prevención & control , Adolescente , Adulto , Australia , Erradicación de la Enfermedad/normas , Detección Precoz del Cáncer , Femenino , Política de Salud , Humanos , Modelos Biológicos , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/transmisión , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/administración & dosificación , Neoplasias del Cuello Uterino/virología , Adulto Joven , Displasia del Cuello del Útero/prevención & control , Displasia del Cuello del Útero/virologíaRESUMEN
INTRODUCTION: Animal trading between countries with different small ruminant lentivirus infectious status is a potential danger for the reintroduction of eradicated genotypes. This was the case in 2017 with the importation of a large flock of seropositive goats into Switzerland. The handling of this case permitted us to test the preventive measures in place. The coordination between the local veterinarian and the cantonal and federal veterinary authorities worked efficiently and rapidly involved the national reference center in the investigations. This case posed a challenge for the reference center and enabled scrutiny of the applied diagnostic tests. ELISA and western blot provided consistent results and pointed to an unusually high infection rate in the flock. This was confirmed by the isolation of several viruses from different organs and cells, demonstrating that the spleen is particularly well suited for isolation of small ruminant lentiviruses. The SU5-ELISA, designed to predict the subtype of the infecting virus, correctly pointed to a B1 subtype as the infectious agent. We confirmed that with this test it is necessary to analyze a representative number of samples from a flock and not just individual sera to obtain reliable results. This analysis permitted us to identify particular amino acid residues in the SU5 peptides that may be crucial in determining the subtype specificity of antibody binding. Different gag-pol and env regions were amplified by PCR using primers designed for this purpose. The phylogenetic analysis revealed a surprisingly high heterogeneity of the sequences, pointing to multiple infections within single animals and the entire flock. In conclusion, this case showed that the defense of the CAEV negative status of the Swiss goat population with respect to the virulent, prototypic B1 subtype of small ruminant lentiviruses, requires, among other measures, a diagnostic facility capable of performing a thorough analysis of the collected samples.
INTRODUCTION: Le commerce d'animaux entre pays où le statut infectieux des lentivirus des petits ruminants est différent constitue un danger potentiel pour la réintroduction de génotypes éradiqués. Ce fut le cas en 2017 avec l'importation d'un grand troupeau de chèvres séropositives en Suisse. Le traitement de cette affaire nous a permis de tester les mesures préventives mises en place. La coordination entre le vétérinaire local et les autorités vétérinaires cantonales et fédérales a été efficace et a impliqué rapidement le centre de référence national dans les enquêtes. Ce cas a constitué un défi pour le centre de référence et a permis d'examiner de près les tests de diagnostic appliqués. Les tests ELISA et Western blot ont fourni des résultats cohérents et ont mis en évidence un taux d'infection anormalement élevé dans le troupeau. Cela a été confirmé par l'isolement de plusieurs virus provenant d'organes et de cellules différents, démontrant que la rate est particulièrement bien adaptée à l'isolement des lentivirus des petits ruminants. Le SU5-ELISA, conçu pour prédire le sous-type du virus infectant, désignait correctement un sous-type B1 en tant qu'agent infectieux. Nous avons confirmé qu'avec ce test, il était nécessaire d'analyser un nombre représentatif d'échantillons d'un troupeau et pas seulement des sérums individuels pour obtenir des résultats fiables. Cette analyse nous a permis d'identifier des résidus d'acides aminés particuliers dans les peptides SU5 qui pourraient jouer un rôle crucial dans la détermination de la spécificité de sous-type de la liaison à l'anticorps. Différentes régions gag-pol et env ont été amplifiées par PCR en utilisant des amorces conçues à cet effet. L'analyse phylogénétique a révélé une hétérogénéité étonnamment élevée des séquences, indiquant de multiples infections chez les animaux isolés et dans l'ensemble du troupeau. En conclusion, cette affaire a montré que la défense du statut négatif CAEV de la population de chèvres suisses vis-à-vis du virus virulent, sous-type B1 des lentivirus des petits ruminants, nécessite, entre autres mesures, un système de diagnostic capable d'effectuer une analyse approfondie des échantillons collectés.
Asunto(s)
Virus de la Artritis-Encefalitis Caprina/fisiología , Erradicación de la Enfermedad/métodos , Ensayo de Inmunoadsorción Enzimática/veterinaria , Enfermedades de las Cabras/diagnóstico , Enfermedades de las Cabras/prevención & control , Infecciones por Lentivirus/veterinaria , Animales , Virus de la Artritis-Encefalitis Caprina/química , Erradicación de la Enfermedad/normas , Ensayo de Inmunoadsorción Enzimática/normas , Genotipo , Cabras , Infecciones por Lentivirus/diagnóstico , Infecciones por Lentivirus/prevención & control , Infecciones por Lentivirus/virología , SuizaRESUMEN
OBJECTIVES: Prisons are major reservoirs of hepatitis C virus (HCV) in which a therapeutic approach has been particularly difficult so far. Our aim was to create a permanent program of HCV elimination in a prison based on a "test and treat" strategy. METHODS: This open-label clinical trial was conducted in the Spanish prison "El Dueso" between May 2016 and July 2017. Viremic patients were treated with a ledipasvir-sofosbuvir regimen (8-12 weeks) according to the 2015 Spanish Guidelines. A teleconsultation program was established to follow-up patients from the hospital. Non-responders were submitted for a phylogenetic analysis and offered retreatment. An evaluation of new cases of HCV infection was performed every 6 months and upon release in all inmates. RESULTS: 847 (99.5%) inmates accepted to participate. HCV antibodies were present in 110 (13.0%) and 86 (10.2%) had detectable viremia. Most of them were genotype 1 or 3 (82.6%) and had Asunto(s)
Antivirales/uso terapéutico
, Bencimidazoles/administración & dosificación
, Erradicación de la Enfermedad/tendencias
, Exposición a Riesgos Ambientales/efectos adversos
, Fluorenos/administración & dosificación
, Hepatitis C Crónica/prevención & control
, Prisiones
, Uridina Monofosfato/análogos & derivados
, Adulto
, Anciano
, Erradicación de la Enfermedad/métodos
, Erradicación de la Enfermedad/normas
, Femenino
, Estudios de Seguimiento
, Hepacivirus/efectos de los fármacos
, Hepacivirus/aislamiento & purificación
, Anticuerpos contra la Hepatitis C/aislamiento & purificación
, Hepatitis C Crónica/sangre
, Hepatitis C Crónica/transmisión
, Hepatitis C Crónica/virología
, Humanos
, Masculino
, Persona de Mediana Edad
, Guías de Práctica Clínica como Asunto
, Prisioneros
, Evaluación de Programas y Proyectos de Salud
, Sofosbuvir
, España
, Respuesta Virológica Sostenida
, Uridina Monofosfato/administración & dosificación
, Carga Viral
, Viremia/diagnóstico
, Viremia/tratamiento farmacológico
, Viremia/virología
, Adulto Joven
RESUMEN
The Global Certification Commission (GCC), Regional Certification Commissions (RCCs), and National Certification Committees (NCCs) provide a framework of independent bodies to assist the Global Polio Eradication Initiative (GPEI) in certifying and maintaining polio eradication in a standardized, ongoing, and credible manner. Their members meet regularly to comprehensively review population immunity, surveillance, laboratory, and other data to assess polio status in the country (NCC), World Health Organization (WHO) region (RCC), or globally (GCC). These highly visible bodies provide a framework to be replicated to independently verify measles and rubella elimination in the regions and globally.
Asunto(s)
Erradicación de la Enfermedad/organización & administración , Erradicación de la Enfermedad/normas , Salud Global , Sarampión/prevención & control , Poliomielitis/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Certificación , Humanos , Vigilancia en Salud PúblicaRESUMEN
BACKGROUND: Faced with the challenges of immigration, the opening of the Trans-Saharan road and the increase in the volume of trade with sub-Saharan Africa, there is a steady increase in the number of malaria cases. An introduction of the disease in the Maghreb is possible. OBJECTIVE: The general objective is to take stock of the epidemiological situation and the malaria control strategy in the Maghreb countries. METHODS: This is a synthesis of data from a literature search on: PubMed (publications), International and national reports (epidemiology and strategies). RESULTS: In 1979, Tunisia became the second Maghreb country to eliminate malaria after Libya (the last local case in 1973). In 1997, when 76 cases were recorded, Morocco embarked on a new national strategy aimed at the elimination of indigenous malaria by the end of 2005. In Algeria, after a phase of control by existence of P. vivax and P. malaria microspheres, the country is in the maintenance phase and no cases were recorded between 2013 and 2016. In Mauritania, even though malaria transmission is generally low, this parasitosis remains a problem public health. And the strategies of struggle and the contribution of scientific research remain below expectations. CONCLUSION: With the exception of Mauritania, the countries of the Great Arab Maghreb have practically eradicated malaria, even though the maintenance phase is underway in Algeria and cases imported from sub-Saharan Africa continue to be registered.
Asunto(s)
Erradicación de la Enfermedad/tendencias , Malaria/epidemiología , Malaria/prevención & control , África del Norte/epidemiología , Argelia/epidemiología , Erradicación de la Enfermedad/métodos , Erradicación de la Enfermedad/organización & administración , Erradicación de la Enfermedad/normas , Humanos , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Control de Infecciones/normas , Marruecos/epidemiología , Túnez/epidemiologíaRESUMEN
The fight against tuberculosis remains a priority for world leaders: a re-emerging disease in developed countries, endemic elsewhere, it was declared in 1993, as a "world emergency" by the World Health Organization (WHO). The aim of programs is to prevent infection from spreading and perpetuating; the recommended strategies were the subject of common consent by expert committees convened by international agencies, primarily the WHO. As a result, programs of the Maghreb countries have great similarities. Though the regression in cases's number, especially primary and post-primary forms, as well as extensive, deleterious pulmonary tuberculosis in adults, the endemic persists. The proportion of extra-pulmonary tuberculosis (PET) is high. Control of "contacts" would be lacking or delayed in almost half of the cases. The cover by an effective treatment of these cases in Libya and in Mauritania stays below the required 85 %. Taken as a whole, the constituent countries of the Maghreb entity count approximately 78 000 tuberculosis patients for a population close to 100 million inhabitants, with an incidence rate of 76 for 100 000. Reducing the incidence of tuberculosis by 90 % and the mortality by 95%, to ensure that by the end of 2035 tuberculosis is no longer a public health problem is a goal within the reach of Maghreb countries. It can be postulated that by this deadline, the conditions for success will be met.
Asunto(s)
Erradicación de la Enfermedad , Tuberculosis/prevención & control , África del Norte/epidemiología , Antituberculosos/uso terapéutico , Erradicación de la Enfermedad/métodos , Erradicación de la Enfermedad/organización & administración , Erradicación de la Enfermedad/normas , Erradicación de la Enfermedad/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Incidencia , Control de Infecciones/métodos , Control de Infecciones/organización & administración , Control de Infecciones/normas , Control de Infecciones/tendencias , Objetivos Organizacionales , Medicina Preventiva/organización & administración , Medicina Preventiva/normas , Medicina Preventiva/tendencias , Tuberculosis/epidemiología , Tuberculosis/historia , Tuberculosis/terapia , Vacunas contra la Tuberculosis/uso terapéutico , Tuberculosis Pulmonar/tratamiento farmacológico , Organización Mundial de la SaludRESUMEN
The primary aim of the Danish enterovirus (EV) surveillance system is to document absence of poliovirus infection. The conflict in Syria has left many children unvaccinated and movement from areas with polio cases to Europe calls for increased awareness to detect and respond to virus-transmission in a timely manner. We evaluate the national EV laboratory surveillance, to generate recommendations for system strengthening. The system was analysed for completeness of viral typing analysis and clinical information and timeliness of specimen collection, laboratory results and reporting of clinical information. Of 23,720 specimens screened, 2,202 (9.3%) were EV-positive. Submission of cerebrospinal fluid and faecal specimens from primary diagnostic laboratories was 79.5% complete (845/1,063), and varied by laboratory and patient age. EV genotypes were determined in 68.5% (979/1,430) of laboratory-confirmed cases, clinical information was available for 63.1% (903/1,430). Primary diagnostic results were available after a median of 1.4 days, typing results after 17 days, detailed clinical information after 33 days. The large number of samples typed demonstrated continued monitoring of EV-circulation in Denmark. The system could be strengthened by increasing the collection of supplementary faecal specimens, improving communication with primary diagnostic laboratories, adapting the laboratory typing methodology and collecting clinical information with electronic forms.
Asunto(s)
Técnicas de Laboratorio Clínico/normas , Notificación de Enfermedades/normas , Infecciones por Enterovirus/epidemiología , Infecciones por Enterovirus/microbiología , Enterovirus/aislamiento & purificación , Vigilancia de la Población/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Técnicas de Laboratorio Clínico/estadística & datos numéricos , Dinamarca/epidemiología , Erradicación de la Enfermedad/normas , Erradicación de la Enfermedad/estadística & datos numéricos , Notificación de Enfermedades/estadística & datos numéricos , Enterovirus/clasificación , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Prevalencia , Garantía de la Calidad de Atención de Salud , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto JovenRESUMEN
BACKGROUND: In July 2014, an outbreak of Ebola virus disease (EVD) started in Pujehun district, Sierra Leone. On January 10th, 2015, the district was the first to be declared Ebola-free by local authorities after 49 cases and a case fatality rate of 85.7%. The Pujehun outbreak represents a precious opportunity for improving the body of work on the transmission characteristics and effects of control interventions during the 2014-2015 EVD epidemic in West Africa. METHODS: By integrating hospital registers and contact tracing form data with healthcare worker and local population interviews, we reconstructed the transmission chain and investigated the key time periods of EVD transmission. The impact of intervention measures has been assessed using a microsimulation transmission model calibrated with the collected data. RESULTS: The mean incubation period was 9.7 days (range, 6-15). Hospitalization rate was 89%. The mean time from the onset of symptoms to hospitalization was 4.5 days (range, 1-9). The mean serial interval was 13.7 days (range, 2-18). The distribution of the number of secondary cases (R 0 = 1.63) was well fitted by a negative binomial distribution with dispersion parameter k = 0.45 (95% CI, 0.19-1.32). Overall, 74.3% of transmission events occurred between members of the same family or extended family, 17.9% in the community, mainly between friends, and 7.7% in hospital. The mean number of contacts investigated per EVD case raised from 11.5 in July to 25 in September 2014. In total, 43.0% of cases were detected through contact investigation. Model simulations suggest that the most important factors determining the probability of disease elimination are the number of EVD beds, the mean time from symptom onset to isolation, and the mean number of contacts traced per case. By assuming levels and timing of interventions performed in Pujehun, the estimated probability of eliminating an otherwise large EVD outbreak is close to 100%. CONCLUSIONS: Containment of EVD in Pujehun district is ascribable to both the natural history of the disease (mainly transmitted through physical contacts, long generation time, overdispersed distribution of secondary cases per single primary case) and intervention measures (isolation of cases and contact tracing), which in turn strongly depend on preparedness, population awareness, and compliance. Our findings are also essential to determine a successful ring vaccination strategy.
Asunto(s)
Brotes de Enfermedades , Ebolavirus , Fiebre Hemorrágica Ebola/epidemiología , Fiebre Hemorrágica Ebola/prevención & control , Adolescente , Adulto , Niño , Preescolar , Simulación por Computador , Erradicación de la Enfermedad/métodos , Erradicación de la Enfermedad/organización & administración , Erradicación de la Enfermedad/normas , Brotes de Enfermedades/prevención & control , Familia , Femenino , Fiebre Hemorrágica Ebola/transmisión , Hospitalización/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Modelos Teóricos , Sierra Leona/epidemiología , Vacunación , Adulto JovenAsunto(s)
Poliomielitis/prevención & control , Vacuna Antipolio Oral , Poliovirus , Erradicación de la Enfermedad/métodos , Erradicación de la Enfermedad/normas , Brotes de Enfermedades/prevención & control , Salud Global , Humanos , Poliomielitis/transmisión , Poliomielitis/virología , Poliovirus/patogenicidad , Vacuna Antipolio Oral/efectos adversosRESUMEN
India is a signatory to World Health Assembly resolution for elimination of lymphatic filariasis (LF) and National Health Policy has set the goal of LF elimination by 2015. Annual mass drug administration (MDA) is ongoing in endemic districts since 1996-97. Compliance rate is a crucial factor in achieving elimination and was assessed in three districts of Tamil Nadu for 10th and 11th treatment rounds (TRs). An in-depth study assessed the impact of social mobilization by drug distributors (DDs) in two areas from each of the three districts. Overall coverage and compliance for assessed TRs were 76.3 and 67.7% which is below the optimum level to achieve LF elimination. Modifiable determinants continue to be the reason for non-consumption even in the 11th TR and 20.8% were systematic non-compliers. In 76.4% of the cases, DDs failed to adhere to three mandatory visits as per the guidelines. Number of visits by DDs in relation to low and high MDA coverage areas showed a significant relationship (P ≤ 0.000). MDA is limited to drug distribution alone and efforts by DDs in preparing the community were inadequate. Probable means to meet the challenges in preparation of the community is discussed.
Asunto(s)
Servicios de Salud Comunitaria/organización & administración , Erradicación de la Enfermedad/métodos , Filariasis Linfática/prevención & control , Filaricidas/administración & dosificación , Cumplimiento de la Medicación/estadística & datos numéricos , Servicios Preventivos de Salud/organización & administración , Albendazol/administración & dosificación , Albendazol/provisión & distribución , Albendazol/uso terapéutico , Animales , Agentes Comunitarios de Salud/organización & administración , Participación de la Comunidad , Dietilcarbamazina/administración & dosificación , Dietilcarbamazina/uso terapéutico , Erradicación de la Enfermedad/normas , Esquema de Medicación , Filariasis Linfática/tratamiento farmacológico , Filariasis Linfática/epidemiología , Enfermedades Endémicas/prevención & control , Filaricidas/provisión & distribución , Filaricidas/uso terapéutico , Salud Global , Política de Salud , Visita Domiciliaria , Humanos , India/epidemiología , Ivermectina/administración & dosificación , Ivermectina/provisión & distribución , Ivermectina/uso terapéutico , Cumplimiento de la Medicación/psicología , Microfilarias/efectos de los fármacos , Microfilarias/crecimiento & desarrollo , Programas Nacionales de Salud/organización & administración , Recursos HumanosAsunto(s)
Erradicación de la Enfermedad/normas , Medicina Familiar y Comunitaria/normas , Infecciones por VIH/prevención & control , VIH , Tamizaje Masivo/normas , Canadá , Lista de Verificación , Erradicación de la Enfermedad/métodos , Medicina Familiar y Comunitaria/métodos , Humanos , Tamizaje Masivo/métodos , Guías de Práctica Clínica como AsuntoRESUMEN
OBJECTIVE: To assess parent's knowledge and perceptions surrounding polio and polio vaccination, self-reported participation in polio supplementary immunization activities (SIAs) targeting children aged < 5 years, and reasons for non-participation. METHODS: The mixed methods study began with a cross-sectional survey in Karachi, Pakistan. A structured questionnaire was administered to assess parental knowledge of polio and participation in polio SIAs conducted in September and October 2011. Additionally, 30 parents of Pashtun ethnicity (a high-risk group) who refused to vaccinate their children were interviewed in depth to determine why. Descriptive and bivariate analyses by ethnic and socioeconomic group were performed for quantitative data; thematic analysis was conducted for qualitative interviews with Pashtun parents. FINDINGS: Of 1017 parents surveyed, 412 (41%) had never heard of polio; 132 (13%) did not participate in one SIA and 157 (15.4%) did not participate in either SIA. Among non-participants, 34 (21.6%) reported not having been contacted by a vaccinator; 116 (73.9%) reported having refused to participate, and 7 (4.5%) reported that the child was absent from home when the vaccinator visited. Refusals clustered in low-income Pashtun (43/441; 9.8%) and high-income families of any ethnic background (71/153; 46.4%). Low-income Pashtuns were more likely to not have participated in polio SIAs than low-income non-Pashtuns (odds ratio, OR: 7.1; 95% confidence interval, CI: 3.47-14.5). Reasons commonly cited among Pashtuns for refusing vaccination included fear of sterility; lack of faith in the polio vaccine; scepticism about the vaccination programme, and fear that the vaccine might contain religiously forbidden ingredients. CONCLUSION: In Karachi, interruption of polio transmission requires integrated and participatory community interventions targeting high-risk populations.
Asunto(s)
Erradicación de la Enfermedad/normas , Conocimientos, Actitudes y Práctica en Salud/etnología , Madres/psicología , Poliomielitis/prevención & control , Vacunas contra Poliovirus/administración & dosificación , Preescolar , Estudios Transversales , Toma de Decisiones , Erradicación de la Enfermedad/métodos , Padre/psicología , Padre/estadística & datos numéricos , Femenino , Humanos , Programas de Inmunización/organización & administración , Programas de Inmunización/estadística & datos numéricos , Lactante , Entrevistas como Asunto , Masculino , Madres/estadística & datos numéricos , Pakistán/epidemiología , Poliomielitis/etnología , Poliomielitis/inmunología , Investigación Cualitativa , Medición de Riesgo , Autoinforme , Encuestas y Cuestionarios , Organización Mundial de la SaludAsunto(s)
Erradicación de la Enfermedad/organización & administración , Guías como Asunto/normas , Sarampión/prevención & control , Vigilancia de la Población/métodos , Desarrollo de Programa , Rubéola (Sarampión Alemán)/prevención & control , Recolección de Datos , Erradicación de la Enfermedad/normas , Brotes de Enfermedades/prevención & control , Implementación de Plan de Salud/organización & administración , Implementación de Plan de Salud/normas , Humanos , Programas de Inmunización/organización & administración , Sarampión/diagnóstico , Sarampión/epidemiología , Sarampión/transmisión , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/transmisión , Síndrome de Rubéola Congénita/prevención & control , Organización Mundial de la SaludRESUMEN
BACKGROUND: Active case detection (ACD) significantly contributes to early detection and treatment of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL) cases and is cost effective. This paper evaluates the performance and feasibility of adapting ACD strategies into national programs for VL elimination in Bangladesh, India and Nepal. METHODS: The camp search and index case search strategies were piloted in 2010-11 by national programs in high and moderate endemic districts / sub-districts respectively. Researchers independently assessed the performance and feasibility of these strategies through direct observation of activities and review of records. Program costs were estimated using an ingredients costing method. RESULTS: Altogether 48 camps (Bangladesh-27, India-19, Nepal-2) and 81 index case searches (India-36, Nepal-45) were conducted by the health services across 50 health center areas (Bangladesh-4 Upazillas, India-9 PHCs, Nepal-37 VDCs). The mean number of new case detected per camp was 1.3 and it varied from 0.32 in India to 2.0 in Bangladesh. The cost (excluding training costs) of detecting one new VL case per camp varied from USD 22 in Bangladesh, USD 199 in Nepal to USD 320 in India. The camp search strategy detected a substantive number of new PKDL cases. The major challenges faced by the programs were inadequate preparation, time and resources spent on promoting camp awareness through IEC activities in the community. Incorrectly diagnosed splenic enlargement at camps probably due to poor clinical examination skills resulted in a high proportion of patients being subjected to rK39 testing. CONCLUSION: National programs can adapt ACD strategies for detection of new VL/PKDL cases. However adequate time and resources are required for training, planning and strengthening referral services to overcome challenges faced by the programs in conducting ACD.